Raymond James analyst Michael Rose upgrades Glacier Bancorp (NYSE:GBCI) from Market Perform to Outperform and announces $51 price target.
CorMedix Inc. Announces Commercial And Operational Updates Related To Its Business And Anticipated Launch Of DefenCath
CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced